BR9611986A - Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos - Google Patents

Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos

Info

Publication number
BR9611986A
BR9611986A BR9611986A BR9611986A BR9611986A BR 9611986 A BR9611986 A BR 9611986A BR 9611986 A BR9611986 A BR 9611986A BR 9611986 A BR9611986 A BR 9611986A BR 9611986 A BR9611986 A BR 9611986A
Authority
BR
Brazil
Prior art keywords
compounds
preparation
pharmaceutical composition
same pharmaceutical
process compounds
Prior art date
Application number
BR9611986A
Other languages
English (en)
Inventor
Dider Oustric
Pierre Casellas
Joseph Millan
Martine Sarran
Murielle Rinaldi
Francis Barth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9611986A publication Critical patent/BR9611986A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9611986A 1995-12-08 1996-12-06 Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos BR9611986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514547A FR2742148B1 (fr) 1995-12-08 1995-12-08 Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR1996/001953 WO1997021682A1 (fr) 1995-12-08 1996-12-06 Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides

Publications (1)

Publication Number Publication Date
BR9611986A true BR9611986A (pt) 1999-02-17

Family

ID=9485291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611986A BR9611986A (pt) 1995-12-08 1996-12-06 Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos

Country Status (34)

Country Link
US (1) US5925768A (pt)
EP (2) EP0868420B1 (pt)
JP (1) JP3510270B2 (pt)
KR (1) KR100488610B1 (pt)
CN (1) CN1101813C (pt)
AR (1) AR004364A1 (pt)
AT (1) ATE191211T1 (pt)
AU (1) AU718763B2 (pt)
BR (1) BR9611986A (pt)
CA (1) CA2239489C (pt)
CZ (1) CZ294307B6 (pt)
DE (1) DE69607484T2 (pt)
DK (1) DK0868420T3 (pt)
EE (1) EE04674B1 (pt)
ES (1) ES2148820T3 (pt)
FR (1) FR2742148B1 (pt)
GR (1) GR3033626T3 (pt)
HU (1) HUP9901244A3 (pt)
IL (1) IL124801A (pt)
IS (1) IS4765A (pt)
MX (1) MX9804565A (pt)
MY (1) MY115228A (pt)
NO (1) NO310683B1 (pt)
NZ (1) NZ323962A (pt)
PL (1) PL186466B1 (pt)
PT (1) PT868420E (pt)
RU (1) RU2170230C2 (pt)
SI (1) SI0868420T1 (pt)
SK (1) SK283706B6 (pt)
TR (1) TR199801041T2 (pt)
TW (1) TW402594B (pt)
UA (1) UA44913C2 (pt)
WO (1) WO1997021682A1 (pt)
ZA (1) ZA9610299B (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979228A4 (en) * 1997-03-18 2000-05-03 Smithkline Beecham Corp CANNABINOID RECEPTOR AGONISTS
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
CN1377261A (zh) 1999-03-22 2002-10-30 免疫力药品有限公司 治疗免疫疾病
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
CA2387892A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7329651B2 (en) 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005507875A (ja) * 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
AR037352A1 (es) * 2001-11-14 2004-11-03 Schering Corp Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
EP1539693B9 (en) 2002-06-19 2008-10-08 Schering Corporation Cannabinoid receptor agonists
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
JP2005539036A (ja) * 2002-08-21 2005-12-22 グラクソ　グループ　リミテッド ピリミジン化合物
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DE60328033D1 (de) 2002-11-25 2009-07-30 Schering Corp Cannabinoid-rezeptorliganden
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
TW200413328A (en) * 2003-01-02 2004-08-01 Hoffmann La Roche Novel CB 1 receptor inverse agonists
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004078261A1 (en) * 2003-03-07 2004-09-16 The University Court Of The University Of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005080350A1 (en) * 2004-02-23 2005-09-01 Glaxo Group Limited Pyrimidine derivatives as cannabinoid receptor modulators
ES2313304T3 (es) * 2004-02-24 2009-03-01 Glaxo Group Limited Derivados de piridina y su uso como moduladores del receptor cb2.
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006002133A1 (en) * 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
EA012245B1 (ru) * 2004-11-29 2009-08-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эд-Эл-Си Терапевтические пиразоло[3,4-b]пиридины и индазолы
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
US8084451B2 (en) * 2005-01-10 2011-12-27 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US7875647B2 (en) * 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
NZ578063A (en) 2006-12-18 2011-09-30 7Tm Pharma As Cannabinoid CB1 receptor modulators
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
CN101314591B (zh) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
FR2916758B1 (fr) * 2007-06-04 2009-10-09 Sanofi Aventis Sa Derives de 1-benzylpyrazole, leur preparation et leur application en therapeutique
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US8367714B2 (en) * 2007-08-28 2013-02-05 Vanderbilt University Cannabinoid receptor targeted agent
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
CA2698527A1 (en) * 2007-09-20 2009-03-26 Solvay Pharmaceuticals B.V. 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
EP2311443A1 (en) * 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
AU2016277126A1 (en) 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
BR112019011825A2 (pt) 2016-12-12 2019-10-22 Vettore, LLC composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
US10420089B2 (en) 2017-08-10 2019-09-17 At&T Intellectual Property I, L.P. Adaptive two-stage downlink control channel structure for code block group based fifth generation (5G) or other next generation systems
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
IL124801A (en) 2004-07-25
RU2170230C2 (ru) 2001-07-10
DE69607484D1 (de) 2000-05-04
FR2742148A1 (fr) 1997-06-13
ES2148820T3 (es) 2000-10-16
CA2239489A1 (en) 1997-06-19
AU718763B2 (en) 2000-04-20
EE04674B1 (et) 2006-08-15
CZ294307B6 (cs) 2004-11-10
US5925768A (en) 1999-07-20
TR199801041T2 (xx) 1998-08-21
WO1997021682A1 (fr) 1997-06-19
PT868420E (pt) 2000-08-31
CN1101813C (zh) 2003-02-19
SI0868420T1 (en) 2000-10-31
PL186466B1 (pl) 2004-01-30
ZA9610299B (en) 1997-06-18
JP3510270B2 (ja) 2004-03-22
EP0885889A3 (fr) 1999-01-27
JP2000502080A (ja) 2000-02-22
PL327177A1 (en) 1998-11-23
NO310683B1 (no) 2001-08-13
SK75898A3 (en) 1999-01-11
EP0868420B1 (fr) 2000-03-29
CA2239489C (en) 2006-05-09
TW402594B (en) 2000-08-21
DK0868420T3 (da) 2000-08-21
FR2742148B1 (fr) 1999-10-22
GR3033626T3 (en) 2000-10-31
KR100488610B1 (ko) 2005-09-26
CZ177598A3 (cs) 1998-10-14
AU1101097A (en) 1997-07-03
EP0885889A2 (fr) 1998-12-23
HUP9901244A2 (hu) 1999-08-30
ATE191211T1 (de) 2000-04-15
NO982589D0 (no) 1998-06-05
MX9804565A (es) 1998-09-30
EE9800171A (et) 1998-12-15
KR19990072004A (ko) 1999-09-27
HUP9901244A3 (en) 2000-12-28
IL124801A0 (en) 1999-01-26
MY115228A (en) 2003-04-30
EP0868420A1 (fr) 1998-10-07
IS4765A (is) 1998-06-08
AR004364A1 (es) 1998-11-04
DE69607484T2 (de) 2000-10-26
NZ323962A (en) 1999-05-28
CN1207731A (zh) 1999-02-10
NO982589L (no) 1998-08-03
UA44913C2 (uk) 2002-03-15
SK283706B6 (sk) 2003-12-02

Similar Documents

Publication Publication Date Title
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9707251A (pt) Compostos processo para a preparação dos mesmos e composições farmacêuticas
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9504509A (pt) Composto processo para sua preparaçao e formulaçao farmaceûtica
BR9602802A (pt) Derivados de naftaleno processo para a preparação dos mesmos e compostos
PT850948E (pt) Derivados propiofenona e processo para a preparacao dos mesmos
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9611198A (pt) Composto processo de preparação do mesmo e composição farmacêutica
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9605354A (pt) Composto composição farmacêutica processo para a produção do composto e uso
BR9609467A (pt) Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária
BR9708014A (pt) Derivados de arilglicinamida processo para a preparação deles e composições farmacêuticas contendo estes compostos
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
BR9600339A (pt) Compostos composições farmacêuticas processo para a preparação de um composto e uso dos mesmos
BR9607264A (pt) Composto derivado do isotiuréia composição farmacêutica uso de tal composto e processo para a preparação dos mesmos
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
BR9605046A (pt) Compostos preparação farmacêutica uso dos compostos e processo para a fabricação dos mesmos
BR9606596A (pt) Composto processo para preparar um composto composição cosmética ou farmacéutica e uso de um composto
BR9406924A (pt) Composto processo para preparar o mesmo formulaçao farmaceutica e uso de um composto

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: SANOFI-SYNTHELABO (FR)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.